Skip to main content
SpringerLink
Log in

Facilitated Percutaneous Coronary Intervention

  • Chapter
  • First Online:
Primary Angioplasty in Acute Myocardial Infarction

Part of the book series: Contemporary Cardiology ((CONCARD))

  • 804 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003 Jan 4; 361(9351): 13–20.

    Google Scholar 

  2. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? The American journal of cardiology. 2003 Oct 1; 92(7): 824–6.

    Google Scholar 

  3. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation. 2004 Aug 31; 110(9): e82–292.

    Google Scholar 

  4. McNamara RL, Herrin J, Bradley EH, Portnay EL, Curtis JP, Wang Y, et al. Hospital improvement in time to reperfusion in patients with acute myocardial infarction, 1999 to 2002. Journal of the American College of Cardiology. 2006 Jan 3; 47(1): 45–51.

    Article  PubMed  Google Scholar 

  5. McNamara RL, Wang Y, Herrin J, Curtis JP, Bradley EH, Magid DJ, et al. Effect of door-to-balloon time on mortality in patients with ST-segment elevation myocardial infarction. Journal of the American College of Cardiology. 2006 Jun 6; 47(11): 2180–6.

    Article  PubMed  Google Scholar 

  6. Tarantini G, Cacciavillani L, Corbetti F, Ramondo A, Marra MP, Bacchiega E, et al. Duration of ischemia is a major determinant of transmurality and severe microvascular obstruction after primary angioplasty: a study performed with contrast-enhanced magnetic resonance. Journal of the American College of Cardiology. 2005 Oct 4; 46(7): 1229–35.

    Article  PubMed  Google Scholar 

  7. Pinto DS, Kirtane AJ, Nallamothu BK, Murphy SA, Cohen DJ, Laham RJ, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006 Nov 7; 114(19): 2019–25.

    Article  PubMed  Google Scholar 

  8. Brodie BR, Hansen C, Stuckey TD, Richter S, Versteeg DS, Gupta N, et al. Door-to-balloon time with primary percutaneous coronary intervention for acute myocardial infarction impacts late cardiac mortality in high-risk patients and patients presenting early after the onset of symptoms. Journal of the American College of Cardiology. 2006 Jan 17; 47(2): 289–95.

    Article  PubMed  Google Scholar 

  9. Gersh BJ, Stone GW, White HD, Holmes DR, Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? Jama. 2005 Feb 23; 293(8): 979–86.

    Article  PubMed  CAS  Google Scholar 

  10. O'Neill WW, Weintraub R, Grines CL, Meany TB, Brodie BR, Friedman HZ, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation. 1992 Dec; 86(6): 1710–7.

    Google Scholar 

  11. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. Journal of the American College of Cardiology. 1999 Dec; 34(7): 1954–62.

    Google Scholar 

  12. Widimsky P, Groch L, Zelizko M, Aschermann M, Bednar F, Suryapranata H. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. European heart journal. 2000 May; 21(10): 823–31.

    Google Scholar 

  13. Fernandez-Aviles F, Alonso JJ, Castro-Beiras A, et al. Primary versus facilitated percutaneous coronary intervention (tenecteplase plus stenting) in patients with ST-elevated myocardial infarction: the final results of the GRACIA-2 randomized trial. European heart journal. 2004; 25 (suppl): 22 (abstr).

    Google Scholar 

  14. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18; 367(9510): 569–78.

    Google Scholar 

  15. Collet JP, Montalescot G, Le May M, Borentain M, Gershlick A. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. Journal of the American College of Cardiology. 2006 Oct 3; 48(7):1326–35.

    Google Scholar 

  16. Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet. 2006 Feb 18; 367(9510): 579–88.

    Article  PubMed  CAS  Google Scholar 

  17. Vermeer F, Oude Ophuis AJ, vd Berg EJ, Brunninkhuis LG, Werter CJ, Boehmer AG, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart (British Cardiac Society). 1999 Oct; 82(4): 426–31.

    CAS  Google Scholar 

  18. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001 Jun 16; 357(9272): 1905–14.

    Article  PubMed  CAS  Google Scholar 

  19. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003 Jul 15; 108(2): 135–42.

    Google Scholar 

  20. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. American heart journal. 2005 Jul; 150(1): 116–22.

    Google Scholar 

  21. Kastrati A, Mehilli J, Schlotterbeck K, Dotzer F, Dirschinger J, Schmitt C, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. Jama. 2004 Feb 25; 291(8): 947–54.

    Google Scholar 

  22. Liem A, Zijlstra F, Ottervanger JP, Hoorntje JC, Suryapranata H, de Boer MJ, et al. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. Journal of the American College of Cardiology. 2000 Mar 1; 35(3): 600–4.

    Google Scholar 

  23. Ashby DT, Dangas G, Aymong EA, Farkouh ME, Mehran R, Lansky AJ, et al. Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. The American journal of cardiology. 2003 Aug 1; 92(3): 319–22.

    Google Scholar 

  24. Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Williams KA, Levine G, et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. Journal of the American College of Cardiology. 2003 Feb 5; 41(3): 386–93.

    Article  PubMed  CAS  Google Scholar 

  25. Chew DP, Bhatt DL, Lincoff AM, Moliterno DJ, Brener SJ, Wolski KE, et al. Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation. 2001 Feb 20; 103(7): 961–6.

    PubMed  CAS  Google Scholar 

  26. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006 Aug 22; 114(8): 774–82.

    Article  PubMed  Google Scholar 

  27. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. The American journal of cardiology. 2003 Oct 15;92(8): 930–5.

    Article  PubMed  Google Scholar 

  28. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002 Feb 5;105(5): 656–62.

    Article  PubMed  Google Scholar 

  29. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation. 2000 Feb 8;101(5): 570–80.

    PubMed  CAS  Google Scholar 

  30. Williams MS, Coller BS, Vaananen HJ, Scudder LE, Sharma SK, Marmur JD. Activation of platelets in platelet-rich plasma by rotablation is speed-dependent and can be inhibited by abciximab (c7E3 Fab; ReoPro). Circulation. 1998 Aug 25; 98(8): 742–8.

    PubMed  CAS  Google Scholar 

  31. van't Hof AW, Ernst N, de Boer MJ, de Winter R, Boersma E, Bunt T, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial. European heart journal. 2004 May; 25(10): 837–46.

    Article  Google Scholar 

  32. Lee DP, Herity NA, Hiatt BL, Fearon WF, Rezaee M, Carter AJ, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation. 2003 Mar 25; 107(11): 1497–501.

    Article  PubMed  Google Scholar 

  33. Gabriel HM, Oliveira JA, da Silva PC, da Costa JM, da Cunha JA. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial. Catheter Cardiovasc Interv. 2006 Aug; 68(2): 218–24.

    Article  PubMed  Google Scholar 

  34. Arntz HR, Schroeder J, Pels K, Schwimmbeck P, Witzenbichler B, Schultheiss HP. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE study. European Heart Journal. 2003; 24 (suppl): 268 (abstr.).

    Article  Google Scholar 

  35. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. The American journal of cardiology. 2002 Sep 1; 90(5):533–6.

    Article  PubMed  CAS  Google Scholar 

  36. Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP, Jr., Dua V, Garringer J, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. The American journal of Cardiology. 2003 Oct 15; 92(8): 977–80.

    Article  PubMed  CAS  Google Scholar 

  37. Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion – results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. European Heart Journal. 2004 Dec; 25(23): 2125–33.

    Article  PubMed  Google Scholar 

  38. Zeymer U, Zahn R, Schiele R, Jansen W, Girth E, Gitt A, et al. Early eptifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST elevation myocardial infarction: results of the randomized integrilin in acute myocardial infarction (INTAMI) pilot trial. European Heart Journal. 2005 Oct; 26(19): 1971–7.

    Article  PubMed  CAS  Google Scholar 

  39. Bellandi F, Maioli M, Leoncini M, Toso A, Dabizzi RP. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. International Journal of Cardiology. 2006 Mar 22; 108(1): 36–42.

    Article  PubMed  Google Scholar 

  40. Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Lins J, et al. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. American Heart Journal. 2006 Oct; 152(4): 668–75.

    Article  PubMed  CAS  Google Scholar 

  41. Maioli M, Bellandi F, Leoncini M, Toso A, Dabizzi RP. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). Journal of the American College of Cardiology. 2007 Apr 10; 49(14): 1517–24.

    Article  PubMed  CAS  Google Scholar 

  42. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. American Heart Journal. 2004 Mar; 147(3): 457–62.

    Article  PubMed  CAS  Google Scholar 

  43. Stone GW, Gersh BJ. Facilitated angioplasty: paradise lost. Lancet. 2006 Feb 18; 367(9510): 543–6.

    Article  PubMed  Google Scholar 

  44. Ellis SG, Armstrong P, Betriu A, Brodie B, Herrmann H, Montalescot G, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. American Heart Journal. 2004 Apr; 147(4): E16.

    Article  PubMed  Google Scholar 

  45. Armstrong PW. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. European Heart Journal. 2006 Jul; 27(13): 1530–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Western Ontario, London, ON, Canada

    Pantelis Diamantouros

Authors
  1. Pantelis Diamantouros
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ing Haan Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pantelis Diamantouros .

Editor information

Editors and Affiliations

    Appendix: Trial Glossary

    Appendix: Trial Glossary

    PACT:

    Plasminogen-activator Angioplasty Compatibility Trial

    PRAGUE:

    PRimary Angioplasty in patients transferred from General community hospitals to specialized PTCA Units with or without Emergency thrombolysis

    GRACIA-2:

    Grupo de Análisis de la Cardiopatía Isquémica Aguda-2 (Primary versus facilitated PCI [tenecteplase plus stenting] in patients with ST-elevated myocardial infarction)

    ASSENT-4:

    Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention-4

    ADVANCE MI:

    Addressing the Value of facilitated Angioplasty after Combination Therapy or Eptifibatide monotherapy in acute Myocardial Infarction

    BRAVE:

    Bavarian Reperfusion Alternatives Evaluation Study Investigators

    HEAP:

    Heparin in Early Patency

    On-TIME:

    Ongoing Tirofiban in Myocardial Infarction Evaluation

    ERAMI:

    Early ReoPro Administration in Myocardial Infarction

    TIGER-PA:

    Tirofiban Given in the Emergency Room before Primary Angioplasty

    INTAMI:

    Integrilin in Acute Myocardial Infarction

    TIMI:

    Thrombolysis in Myocardial Infarction

    TITAN:

    Time to Integrilin Therapy in Acute Myocardial Infarction

    RELAx-AMI:

    Randomized Early Versus Late Abciximab in Acute Myocardial Infarction

    FINESSE:

    Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events

    Rights and permissions

    Reprints and permissions

    Copyright information

    © 2009 Humana Press, a part of Springer Science+Business Media, LLC

    About this chapter

    Cite this chapter

    Diamantouros, P., Lim, I.H. (2009). Facilitated Percutaneous Coronary Intervention. In: Tcheng, J. (eds) Primary Angioplasty in Acute Myocardial Infarction. Contemporary Cardiology. Humana Press. https://doi.org/10.1007/978-1-60327-497-5_8

    Download citation

    • DOI: https://doi.org/10.1007/978-1-60327-497-5_8

    • Published:

    • Publisher Name: Humana Press

    • Print ISBN: 978-1-60327-496-8

    • Online ISBN: 978-1-60327-497-5

    • eBook Packages: MedicineMedicine (R0)

    Publish with us

    Policies and ethics

    Search

    Navigation